Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

(2016)

Medical Benefit

Effective Date: 10/01/15
Next Review Date: 07/20

Preauthorization

No
Review Dates: 09/10, 07/11, 07/12, 05/13, 05/14, 05/15, 07/15, 07/16, 07/17, 07/18, 07/19

Preauthorization is not required.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals:</td>
<td>Interventions of interest are:</td>
<td>Comparators of interest are:</td>
<td>Relevant outcomes include:</td>
</tr>
<tr>
<td>With chronic wounds</td>
<td>• Platelet-rich plasma</td>
<td>• Standard wound care</td>
<td>• Symptoms</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Change in disease status</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Morbid events</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Quality of life</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Treatment-related morbidity</td>
</tr>
<tr>
<td>Individuals:</td>
<td>Interventions of interest are:</td>
<td>Comparators of interest are:</td>
<td>Relevant outcomes include:</td>
</tr>
<tr>
<td>With acute surgical or</td>
<td>• Platelet-rich plasma</td>
<td>• Standard wound care</td>
<td>• Symptoms</td>
</tr>
<tr>
<td>traumatic wounds</td>
<td></td>
<td></td>
<td>• Change in disease status</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Morbid events</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Quality of life</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Treatment-related morbidity</td>
</tr>
</tbody>
</table>

DESCRIPTION

The use of blood-derived growth factor platelet-rich plasma (PRP) has been suggested as a treatment for wounds or other miscellaneous non-orthopedic conditions including but not limited to acute surgical and traumatic wounds and nonhealing ulcers.

SUMMARY OF EVIDENCE

For individuals who have chronic wounds or acute surgical or traumatic wounds who receive PRP, the evidence includes a number of small controlled trials. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. Current results of trials using PRP are mixed, and the studies are limited in both size and quality. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Use of platelet-rich plasma (i.e., autologous blood-derived preparations) is considered investigational for the
treatment of acute or chronic wounds, including surgical wounds and nonhealing ulcers.

POLICY GUIDELINES

Note: This protocol does not address becaplermin.

MEDICARE ADVANTAGE

For Medicare Advantage members there may be potential for benefit under coverage with evidence development (CED).

BACKGROUND

WOUND HEALING TREATMENT

Autologous platelet concentrate suspended in plasma, also known as PRP, can be prepared from samples of centrifuged autologous blood. Exposure to a solution of thrombin and calcium chloride degranulates platelets, releasing various growth factors, and results in the polymerization of fibrin from fibrinogen, creating a platelet gel. The platelet gel can then be applied to wounds or may be used as an adjunct to surgery to promote hemostasis and accelerate healing. In the operating room setting, PRP has been investigated as an adjunct to a variety of periodontal, reconstructive, and orthopedic procedures. For example, bone morphogenetic proteins are a transforming growth factor, and thus PRP has been used in conjunction with bone-replacement grafting (using either autologous grafts or bovine-derived xenograft) in periodontal and maxillofacial surgeries.

PRP is distinguished from fibrin glues or sealants, which have been used for many years as a surgical adjunct to promote local hemostasis at incision sites. Fibrin glue is created from platelet-poor plasma and consists primarily of fibrinogen. Commercial fibrin glues are created from pooled homologous human donors; Tisseel® (Baxter International) and Hemaseel® (Haemacure Corp.) are examples of commercially available fibrin sealants. Autologous fibrin sealants can also be created from platelet-poor plasma. This protocol does not address the use of fibrin sealants.

Wound Closure Outcomes

This protocol addresses the use of PRP for nonorthopedic indications, which include a number of wound closure-related indications.

For this review, the primary end points of interest for the study of wound closure are as follows, consistent with guidance from the U.S. Food and Drug Administration (FDA) for the industry in developing products for the treatment of chronic cutaneous ulcer and burn wounds:

1. Incidence of complete wound closure;
2. Time to complete wound closure (reflecting accelerated wound closure);
3. Incidence of complete wound closure following surgical wound closure;
4. Pain control

REGULATORY STATUS

The FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the
Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Blood products such as PRP are included in these regulations.

Under these regulations, certain products including blood products such as PRP are exempt and therefore, do not follow the traditional FDA regulatory pathway. To date, the FDA has not attempted to regulate activated PRP.  

Numerous PRP preparation systems have been cleared for marketing by the FDA through the 510(k) process. These devices are intended to concentrate patient plasma at the point of care during bone grafting procedures. The use of different devices and procedures can lead to variable concentrations of active platelets and associated proteins, increasing variability between studies of clinical efficacy.

RELATED PROTOCOLS

Bioengineered Skin and Soft Tissue Substitutes
Electrostimulation and Electromagnetic Therapy for Treating Wounds
Negative Pressure Wound Therapy in the Outpatient Setting
Orthopedic Applications of Platelet-Rich Plasma

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

9. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Becaplermin for wound healing. TEC Assessments. 1999;Volume 14:Tab 5. PMID


